We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
-2.4%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.32B
AUM Growth
-$216M
(-3.9%)
Cap. Flow
-$62.5M
Cap. Flow
% of AUM
-1.18%
Top 10 Holdings %
Top 10 Hldgs %
23.94%
Holding
294
New
29
Increased
89
Reduced
98
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$46.6M |
| 2 |
Gilead Sciences
GILD
|
+$37M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$31.1M |
| 4 |
CVS Health
CVS
|
+$27.8M |
| 5 |
Danaher
DHR
|
+$26.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$36.5M |
| 2 |
PNC Financial Services
PNC
|
+$34.3M |
| 3 |
CELG
Celgene Corp
CELG
|
+$32.4M |
| 4 |
AGN
Allergan plc
AGN
|
+$28M |
| 5 |
Centene
CNC
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.2% |
| 2 | Healthcare | 23.21% |
| 3 | Financials | 21.91% |
| 4 | Communication Services | 9.94% |
| 5 | Industrials | 5.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Box
BOX
$4.38B
| $755K | 0.01% |
61,660
-135,010
| -69% | -$1.53M |
|
|
VTAE
227
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $729K | 0.01% |
110,000
+87,392
| +387% | +$795K |
|
228
Allot
ALLT
$377M
| $635K | 0.01% |
122,039
-138,378
| -53% | -$687K |
|
229
Alkermes
ALKS
$8.37B
| $573K | 0.01% |
16,768
+12,221
| +269% | +$483K |
|
230
Citizens Financial Group
CFG
$30.5B
| $572K | 0.01% |
27,321
-1,459
| -5% | -$30.9K |
|
231
Neurocrine Biosciences
NBIX
$18.2B
| $552K | 0.01% |
+13,961
| New | +$554K |
|
232
Standard BioTools
LAB
$306M
| $520K | 0.01% |
64,492
+13,775
| +27% | +$99.3K |
|
233
Mastercard
MA
$496B
| $511K | 0.01% |
5,405
-2,945
| -35% | -$260K |
|
234
Brookdale Senior Living
BKD
$3.68B
| $429K | 0.01% |
27,019
-69,648
| -72% | -$1.06M |
|
|
TBRA
235
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $409K | 0.01% |
50,000
+15,939
| +47% | +$120K |
|
|
ADAP
236
DELISTED
Adaptimmune Therapeutics
ADAP
| $407K | 0.01% |
+50,000
| New | +$409K |
|
237
Lexicon Pharmaceuticals
LXRX
$1.03B
| $359K | 0.01% |
30,000
+5,000
| +20% | +$52.4K |
|
|
CEMP
238
DELISTED
Cempra, Inc.
CEMP
| $350K | 0.01% |
+20,000
| New | +$363K |
|
|
HSTO
239
DELISTED
Histogen Inc. Common Stock
HSTO
| $335K | 0.01% |
783
| – | – |
|
240
Ocular Therapeutix
OCUL
$1.83B
| $290K | 0.01% |
30,000
-5,000
| -14% | -$37.9K |
|
|
NBRV
241
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $269K | 0.01% |
120
+76
| +173% | +$163K |
|
|
XLNX
242
DELISTED
Xilinx Inc
XLNX
| $244K | ﹤0.01% |
+5,147
| New | +$242K |
|
|
VRML
243
DELISTED
Vermillion, Inc.
VRML
| $147K | ﹤0.01% |
100,000
| – | – |
|
244
Acadia Pharmaceuticals
ACAD
$4.45B
| – | – |
-14,595
| Closed | -$520K |
|
245
Ambarella
AMBA
$2.98B
| – | – |
-71,040
| Closed | -$3.96M |
|
246
CALL
Advanced Micro Devices
AMD
$744B
| – | – |
0
| – | -$12.2M |
|
247
AutoNation
AN
$7.31B
| – | – |
-376,144
| Closed | -$22.4M |
|
248
Cardinal Health
CAH
$54.6B
| – | – |
-37,000
| Closed | -$3.3M |
|
249
Cognex
CGNX
$10B
| – | – |
-450,402
| Closed | -$7.61M |
|
|
250
Centene
CNC
$31.7B
| – | – |
-830,650
| Closed | -$27.3M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q1 2016 Portfolio in Review
As of Q1 2016, Polar Capital held 294 positions worth $5.32B, down 3.9% from $5.53B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Polar Capital's Q1 2016 filing shows 29 new, 89 increased, 98 reduced and 32 closed positions. Its largest new stake was Union Pacific: 603,004 shares worth $48M. The largest sale was Bristol-Myers Squibb, an estimated $36.5M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
- Polar Capital's largest Q1 2016 buy was Union Pacific: 603,004 shares worth $48M.
- Polar Capital added most to Gilead Sciences in Q1 2016, an estimated $37M increase.
- Polar Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $36.5M.
- Polar Capital fully exited Centene in Q1 2016, selling an estimated $27.3M.
- Polar Capital's ten largest holdings make up 24% of its $5.32B portfolio in Q1 2016.
- Polar Capital opened 29 new positions and closed 32 in Q1 2016.
- Polar Capital's portfolio value fell 3.9% quarter-over-quarter to $5.32B.
Based on Polar Capital's 13F filing for Q1 2016, filed 16 May 2016.